Cy­to­ki­net­ics is get­ting its shot at a ma­jor PhI­II show­down with Bris­tol My­ers af­ter post­ing pos­i­tive da­ta for a rare car­dio dis­ease. Shares rock­et up

Af­ter los­ing a whole lot of mar­ket con­fi­dence in their lead drug, lit­tle Cy­to­ki­net­ics is now lin­ing up for a cru­cial Phase III piv­otal chal­lenge for the next car­dio drug in the pipeline. And that will put them toe-to-toe against pow­er­house ri­vals at Bris­tol My­ers Squibb, which just 9 months ago put down a $13 bil­lion wa­ger on what will like­ly be the first drug ap­proved for the same rare car­dio con­di­tion the biotech is con­tend­ing for.

Endpoints News

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters